O'Melveny & Myers

    | BY

    clpstaff &clp articles

    WuXi PharmaTech, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, has made its US$212 million initial…

    WuXi PharmaTech, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, has made its US$212 million initial public offering on the New York Stock Exchange. The offering consisted of 15.17 million American depositary shares (ADS) priced at US$14 each, of which 11.98 million were offered by WuXi PharmaTech and 3.19 million were offered by the selling shareholders. O'Melveny & Myers represented the issuer.

    This premium content is reserved for
    China Law & Practice Subscribers.

    • A database of over 3,000 essential documents including key PRC legislation translated into English
    • A choice of newsletters to alert you to changes affecting your business including sector specific updates
    • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
    For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]